Mary Hitt

5.2k total citations
83 papers, 3.9k citations indexed

About

Mary Hitt is a scholar working on Genetics, Molecular Biology and Oncology. According to data from OpenAlex, Mary Hitt has authored 83 papers receiving a total of 3.9k indexed citations (citations by other indexed papers that have themselves been cited), including 46 papers in Genetics, 33 papers in Molecular Biology and 24 papers in Oncology. Recurrent topics in Mary Hitt's work include Virus-based gene therapy research (44 papers), RNA Interference and Gene Delivery (16 papers) and Immunotherapy and Immune Responses (14 papers). Mary Hitt is often cited by papers focused on Virus-based gene therapy research (44 papers), RNA Interference and Gene Delivery (16 papers) and Immunotherapy and Immune Responses (14 papers). Mary Hitt collaborates with scholars based in Canada, United States and United Kingdom. Mary Hitt's co-authors include Frank L. Graham, Jack Gauldie, Christina Addison, Jonathan L. Bramson, Zhou Xing, William J. Muller, Michael Santosuosso, Peter Emtage, Kris Huygen and Richard W. Stokes and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Biological Chemistry and Journal of Clinical Oncology.

In The Last Decade

Mary Hitt

83 papers receiving 3.8k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Mary Hitt Canada	35	1.5k	1.4k	1.3k	1.3k	697	83	3.9k
Nicola La Monica Italy	41	2.3k 1.5×	1.3k 1.0×	1.4k 1.0×	665 0.5×	1.1k 1.6×	103	5.6k
Andrew Zloza United States	28	1.1k 0.7×	1.3k 0.9×	1.3k 0.9×	1.6k 1.3×	343 0.5×	83	3.4k
Mark J. Federspiel United States	39	1.7k 1.1×	3.0k 2.2×	760 0.6×	1.2k 1.0×	749 1.1×	99	4.6k
Andrew J. Bett United States	26	1.9k 1.2×	1.5k 1.1×	519 0.4×	657 0.5×	746 1.1×	46	3.3k
Marvin S. Reitz United States	36	1.3k 0.8×	476 0.3×	1.8k 1.3×	1.5k 1.2×	828 1.2×	90	5.0k
Lung‐Ji Chang United States	35	1.8k 1.2×	992 0.7×	794 0.6×	1.1k 0.8×	592 0.8×	132	4.2k
Óscar R. Burrone Italy	41	1.4k 0.9×	839 0.6×	1.1k 0.8×	565 0.4×	1.6k 2.3×	150	4.9k
Dmitry M. Shayakhmetov United States	39	3.3k 2.2×	3.6k 2.6×	1.5k 1.1×	1.9k 1.5×	1.3k 1.8×	75	6.0k
Dorotheé von Laer Germany	44	1.9k 1.3×	1.9k 1.4×	1.4k 1.1×	1.2k 0.9×	1.6k 2.2×	175	5.6k
Kevin Gorski United States	21	1.0k 0.7×	1.0k 0.7×	2.9k 2.1×	2.4k 1.9×	189 0.3×	29	4.9k

Countries citing papers authored by Mary Hitt

Since Specialization

Citations

This map shows the geographic impact of Mary Hitt's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mary Hitt with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mary Hitt more than expected).

Fields of papers citing papers by Mary Hitt

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mary Hitt. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mary Hitt. The network helps show where Mary Hitt may publish in the future.

Co-authorship network of co-authors of Mary Hitt

This figure shows the co-authorship network connecting the top 25 collaborators of Mary Hitt. A scholar is included among the top collaborators of Mary Hitt based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mary Hitt. Mary Hitt is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Hitt, Mary, et al.. (2023). Mathematical modeling predicts pathways to successful implementation of combination TRAIL-producing oncolytic virus and PAC-1 to treat granulosa cell tumors of the ovary. Cancer Biology & Therapy. 24(1). 2283926–2283926. 1 indexed citations

Han, Xuefei, Kyle Potts, Armin M. Gamper, et al.. (2023). Radiation-Induced Cellular Senescence Reduces Susceptibility of Glioblastoma Cells to Oncolytic Vaccinia Virus. Cancers. 15(13). 3341–3341. 4 indexed citations

Walters, M. N‐I., et al.. (2023). Improved oncolytic activity of a reovirus mutant that displays enhanced virus spread due to reduced cell attachment. Molecular Therapy — Oncolytics. 31. 100743–100743. 2 indexed citations

Fu, Yangxin, et al.. (2022). Establishing combination PAC‐1 and TRAIL regimens for treating ovarian cancer based on patient‐specific pharmacokinetic profiles using in silico clinical trials. SHILAP Revista de lepidopterología. 2(2). 8 indexed citations

Färkkilä, Anniina, Adrianne L. Jenner, Kyle Potts, et al.. (2021). Procaspase-Activating Compound-1 Synergizes with TRAIL to Induce Apoptosis in Established Granulosa Cell Tumor Cell Line (KGN) and Explanted Patient Granulosa Cell Tumor Cells In Vitro. International Journal of Molecular Sciences. 22(9). 4699–4699. 7 indexed citations

Hugh, Judith, Gilbert Bigras, Xiuying Hu, et al.. (2021). DREAM, a possible answer to the estrogen paradox of the Women's Health Initiative Trial. Heliyon. 8(1). e08666–e08666. 2 indexed citations

Garcia, Elizabeth, et al.. (2021). Inhibition of triple negative breast cancer metastasis and invasiveness by novel drugs that target epithelial to mesenchymal transition. Scientific Reports. 11(1). 11757–11757. 17 indexed citations

Noyce, Ryan S., Brian C. Franczak, Mira M. Shenouda, et al.. (2020). Deciphering the Immunomodulatory Capacity of Oncolytic Vaccinia Virus to Enhance the Immune Response to Breast Cancer. Cancer Immunology Research. 8(5). 618–631. 10 indexed citations

Azad, Abul Kalam, Nidhi Gupta, Zhihua Xu, et al.. (2019). RUNX3 Promotes the Tumorigenic Phenotype in KGN, a Human Granulosa Cell Tumor-Derived Cell Line. International Journal of Molecular Sciences. 20(14). 3471–3471. 10 indexed citations

10.

Thapa, Bindu, K Bahadur, Mary Hitt, et al.. (2019). Breathing New Life into TRAIL for Breast Cancer Therapy: Co-Delivery of pTRAIL and Complementary siRNAs Using Lipopolymers. Human Gene Therapy. 30(12). 1531–1546. 14 indexed citations

11.

Potts, Kyle, Desmond Pink, Krista M. Vincent, et al.. (2017). Deletion of F4L (ribonucleotide reductase) in vaccinia virus produces a selective oncolytic virus and promotes anti‐tumor immunity with superior safety in bladder cancer models. EMBO Molecular Medicine. 9(5). 638–654. 36 indexed citations

12.

Santosuosso, Michael, Xizhong Zhang, Sarah McCormick, et al.. (2005). Mechanisms of Mucosal and Parenteral Tuberculosis Vaccinations: Adenoviral-Based Mucosal Immunization Preferentially Elicits Sustained Accumulation of Immune Protective CD4 and CD8 T Cells within the Airway Lumen. The Journal of Immunology. 174(12). 7986–7994. 141 indexed citations

13.

Wang, Jun, Lisa Thorson, Richard W. Stokes, et al.. (2004). Single Mucosal, but Not Parenteral, Immunization with Recombinant Adenoviral-Based Vaccine Provides Potent Protection from Pulmonary Tuberculosis. The Journal of Immunology. 173(10). 6357–6365. 314 indexed citations

14.

Gabaglia, Claudia Raja, et al.. (2004). Life-long systemic protection in mice vaccinated with and adenovirus IL-12 vector requires active infection, macrophages and intact lymph nodes. Vaccine. 23(2). 247–257. 11 indexed citations

15.

Trachtenberg, John, Ants Toi, Joan Sweet, et al.. (2003). A phase I trial of adenovector-mediated delivery of interleukin-2 (AdIL-2) in high-risk localized prostate cancer. Cancer Gene Therapy. 10(10). 755–763. 47 indexed citations

16.

Gyorffy, Steve, Kay Palmer, Thomas J. Podor, Mary Hitt, & Jack Gauldie. (2001). Combined Treatment of a Murine Breast Cancer Model with Type 5 Adenovirus Vectors Expressing Murine Angiostatin and IL-12: A Role for Combined Anti-Angiogenesis and Immunotherapy. The Journal of Immunology. 166(10). 6212–6217. 45 indexed citations

17.

Hitt, Mary, Robin J. Parks, & Frank L. Graham. (1999). 4 Structure and Genetic Organization of Adenovirus Vectors. Cold Spring Harbor Monograph Archive. 36. 61–86. 23 indexed citations

18.

Emtage, Peter, Yonghong Wan, Mary Hitt, et al.. (1999). Adenoviral Vectors Expressing Lymphotactin and Interleukin 2 or Lymphotactin and Interleukin 12 Synergize to Facilitate Tumor Regression in Murine Breast Cancer Models. Human Gene Therapy. 10(5). 697–709. 97 indexed citations

19.

Pützer, Brigitte M., Jonathan L. Bramson, Christina Addison, et al.. (1998). Combination Therapy with Interleukin-2 and Wild-Type p53 Expressed by Adenoviral Vectors Potentiates Tumor Regression in a Murine Model of Breast Cancer. Human Gene Therapy. 9(5). 707–718. 53 indexed citations

20.

Hitt, Mary, Christina Addison, & Frank L. Graham. (1997). Human Adenovirus Vectors for Gene Transfer into Mammalian Cells. Advances in pharmacology. 40. 137–206. 156 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact